Nephros believes that identifying, recruiting and maintaining a solid
management and engineering team are as important as the technology
itself. Experience has often revealed the challenges in "translating"
ideal clinical needs into a practical commercial product. To this end, we
have assembled a team with an invaluable combination of clinical,
engineering and dialysis industry backgrounds, and continue to recruit
such individuals. Thus Nephros retains an unparalleled ability to
balance clinical and commercial requirements, optimizing products and
therapies at very early stages in the development process. With
extensive experience innovating in the medical device domain, the
Nephros team can ensure a constant stream of new product ideas to
continually expand our product line.
Our Management Team
Ernest A. Elgin III - President, CEO
Mr. Elgin has 20 years of career experience, including solid leadership
roles within large and small organizations. He was most recently
Vice President of Business Development and COO for Novaflux
spent four years as Vice President, Healthcare for EHC Group,
a New York based consulting organization providing market and
business development services for healthcare related organizations.
Mr. Elgin has also held product and business development roles with
Becton Dickinson, Olympus America, and E- Z -EM, Inc. Mr. Elgin
started his career as a Financial Analyst with Salomon Brothers.
Mr. Elgin earned his Bachelor of Arts Degree from Queens College
and his MBA from Long Island University.
Gerald J. Kochanski - Chief Financial Officer
Mr. Kochanski is a Certified Public Accountant with over thirty years
of experience in finance and accounting. With a strong track record
in growing companies, he has played a key role in several major
corporate collaborations, successfully completing public and private
financial transactions. Mr. Kochanski joins the company from Lordi
Consulting LLC, where he has served as Director since 2007. Prior to
his tenure at Lordi, he spent three years with American Water
Enterprises, Inc. as Chief Financial Officer and from 1998 through
2004 was Chief Financial Officer for Scanvec Amiable Limited. Prior
to 1991, Mr. Kochanski demonstrated his financialand management
leadership at Gist - Brocades Food Ingredients, Inc., Keystone
Franklin, Inc. and Airshields, Inc. Mr. Kochanski started his career
in public accounting at Price Waterhouse & Co.
Mr. Kochanski earned his Bachelor's degree and MBA from LaSalle
University.
Our Board of Directors James S. Scibetta - Chairman of the Board - Mr. Scibetta is the
Chief Financial Officer of Pacira Pharmaceuticals. Prior to Pacira,
Mr. Scibetta was Chief Financial Officer of Nasdaq-listed Bioenvision,
Inc. from December 2006 until its acquisition by Genzyme, Inc. in October
2007.From September 2001 to November 2006, Mr. Scibetta was EVP
and CFO of Merrimack Pharmaceuticals, Inc., and he was a member of
the Board of Directors of Merrimack from April 1998 to March 2004.
Mr. Scibetta formerly served as a senior investment banker at Shattuck
Hammond Partners, LLC from 1997 to 2001 and Paine Webber Inc.
from 1988 to 1997, providing capital acquisition, mergers and
acquisitions,and strategic advisory services to healthcare companies.
From 2001 to 2008, Mr.Scibetta served as a member of the Board of
Directors and Audit Committee Chairman of Labopharm, Inc.(Nasdaq: DDSS).
Mr. Scibetta holds a B.S. in Physics from Wake Forest University,
and an M.B.A. in Finance from the University of Michigan.He completed
executive education studies in the Harvard Business School Leadership
& Strategy in Pharmaceuticals and Biotechnology program.
Lawrence J. Centella - Mr. Centella serves as president of Renal
Patient Services, LLC. a company that owns and operates dialysis
centers, and has served in this capacity since June 1998. From 1997-
1998, Mr. Centella served as executive vice president and chief operating
officer of Gambro Healthcare, Inc., an integrated dialysis company that
manufactured dialysis equipment, supplied dialysis equipment and
operated dialysis clinics. From 1993 to 1997, Mr. Centella served as
president and chief executive officer of Gambro Healthcare Patient Services
Inc. Prior to that, Mr. Centella served as president of COBE Renal Care, Inc,
Gambro-Hospal, Inc, LADA International, Inc and Gambro, Inc. Mr. Centella
is also the founder of LADA International, Inc. Mr. Centella received a BS
from DePaul University.
Paul A. Mieyal - Dr.Mieyal is a Vice President and the Director of Life
Sciences Investments of Wexford Capital LLC. Prior to that, he was
Vice President in charge of health care investments for Wechsler &
Co., Inc. a private investment firm and registered broker dealer. Dr.
Mieyal serves as director of Nile Therapeutics, Inc.,and several private
companies. Dr. Mieyal received his Ph.D. in pharmacology from New
York Medical College, a B.A. in chemistry and psychology from Case
Western Reserve University, and is a Chartered Financial Analyst.
Arthur H. Amron - Mr. Amron is a partner of Wexford Capital and
serves as its General Counsel. He actively participates in various
private equity transactions, particularly in the bankruptcy and
restructuring areas, and has served on the board committees of a
number of public and private companies in which Wexford has held
investments. Mr. Amron holds a JD from Harvard University, a B.A.
in political theory from Colgate University, and is a member of the
New York bar.
Ernest A. Elgin III - Mr. Elgin has 20 years of career experience, including
solid leadershiproles within large and small organizations. He was
most recently Vice President of Business Development and COO for
Novaflux spent four years as Vice President, Healthcare for EHC
Group, a New York based consulting organization providing market
and business development services for healthcare related organizations.
Mr. Elgin has also held product and business development roles with
Becton Dickinson, Olympus America, and E- Z -EM, Inc. Mr. Elgin
started his career as a Financial Analyst with Salomon Brothers.
Mr. Elgin earned his Bachelor of Arts Degree from Queens College
and his MBA from Long Island University.
Scientific Advisory Board
John T. Daugirdas, MD - University of Illinoisat Chicago School of
Medicine Associate. Chief of Staff for Research and Development,
VA Chicago - Westside Medical Center. Co-author The Handbook
of Dialysis.
Detlef Krieter, MD - Fellow at the University of Goettingen and
University of Wuerzburg, Germany, and University of Montpellier and
Renal Research and Training Institute, Montpellier, France;
consultant at the Nephrology Center of Lower Saxony, Germany.
Active researcher in the field o f extracorporeal renal replacement
therapies.
Leonard Stern, MD FACP - Medical Director at Columbia University
Dialysis Center, an Assistant Professor of Clinical Medicine,
Columbia University, College of Physician and Surgeons.
|
